Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.
|
31679083 |
2020 |
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Non-small cell lung cancer (NSCLC), since the recognition of epidermal growth factor receptor (EGFR) mutations that sensitized tumors to EGFR tyrosine kinase inhibitors, has been a poster child for precision oncology in solid tumors.
|
31567128 |
2020 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Using ICP-MS and confocal microscopy, we could demonstrate that our conjugate has high selectivity for the EGFR receptor, which is a crucial oncological target because it is overexpressed and/or deregulated in a variety of solid tumors.
|
31339225 |
2020 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Nimotuzuma is an epidermal growth factor receptor (EGRF) monoclonal antibody agent, which has been exploited in varied solid tumors.
|
31001861 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Epidermal growth factor receptor (EGFR) is a rational target for cancer therapy, because its overexpression plays an important oncogenic role in a variety of solid tumors; however, EGFR-targeted antibody-drug conjugate (ADC) therapy for esophageal squamous cell carcinoma (ESCC) is exceedingly rare.
|
30372581 |
2019 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The epidermal growth factor receptor (EGFR) is overexpressed in numerous solid tumors and is the subject of extensive therapeutic efforts.
|
31444232 |
2019 |
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Mutations in the epidermal growth factor receptor (<i>EGFR</i>) are associated with various solid tumors.
|
31185703 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In this review, we provide deep insights into the development of EGFR-targeting nanomedicines and discuss various types of nanoscale DDSs (e.g., organic and inorganic nanoparticles) for targeting of the EGFR-positive solid tumors such as CRC.
|
31563999 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
For patients with EGFR mutations in LA-MPEs, the response to EGFR TKIs seems to be worse for pleural effusions than for solid tumors.
|
28934846 |
2018 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
However, a direct correlation between the expression pattern of p120ctn in solid tumors and the therapeutic effect of EGFR-TKIs has not yet been demonstrated.
|
27299185 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our data support further investigation of RN765C in the clinic to treat EGFR expressing solid tumors.
|
30323890 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Dual targeting of EGFR and HER2 is a proven anticancer strategy for the treatment of solid tumors.
|
30041137 |
2018 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
This phase 1/2 study evaluated the safety, pharmacokinetics, and efficacy of depatux-m in patients who had advanced solid tumors with known wild-type EGFR overexpression, amplification, or mutated EGFR variant III.
|
29533458 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The epidermal growth factor receptor (EGFR) acts as a driver oncogene in many types of solid tumors.
|
29539615 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The use of SMF is promising in the treatment of solid tumors; however, it appears to interfere with EGFR-targeted therapy.
|
30061221 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We report results for pictilisib (GDC-0941, a class I pan-PI3K inhibitor) plus erlotinib (an EGFR tyrosine kinase inhibitor) in patients with advanced solid tumors.
|
28798270 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our results demonstrate that rE/CUS is a potential therapeutic strategy for treating EGFR-positive solid tumors.
|
28445134 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR.
|
28349167 |
2017 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
A CA-repeat polymorphism in intron-1 (CA-SSR-1) of the EGFR gene is reported to influence EGFR expression and is associated with features of various solid tumors and outcomes of cancer patients.
|
28150908 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Beyond antibody to Her2/NEU and EGFR, very few antibody-based and no CAR-based therapies have seen broad clinical application for solid tumors.
|
28871274 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
AE = adverse event CI = confidence interval C<sub>ss,max</sub> = maximum steady-state plasma concentration DCR = disease control rate EGFR = epidermal growth factor receptor ILD = interstitial lung disease MTC = medullary thyroid cancer ORR = objective response rate PFS = progression-free survival PK = pharmacokinetics RECIST = Response Evaluation Criteria in Solid Tumors RET = re-arranged during transfection SAE = serious adverse event VEGFR = vascular endothelial growth factor receptor.
|
27819766 |
2017 |
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Purpose The Iressa Mutation-Positive Multicentre Treatment Beyond ProgRESsion Study (IMPRESS) compared the continuation of gefitinib plus chemotherapy with placebo plus chemotherapy in patients with epidermal growth factor receptor ( EGFR) mutation-positive advanced non-small-cell lung cancer with progression (Response Evaluation Criteria in Solid Tumors 1.1) after first-line gefitinib.
|
28968167 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The findings suggested that patients with ALK rearrangements are more likely to be young, have EGFR wild-type, and more likely to exhibit mucus secretion, solid tumor growth, lymph node metastasis and pleural metastasis.
|
26888425 |
2016 |
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The analysis included advanced EGFR-mutated NSCLC patients treated with first-line TKI who experienced RECIST progression between June 2010 and July 2012.
|
26315967 |
2016 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors.
|
26434585 |
2016 |